Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort

Genetics in Medicine

Volumn 9, Issue 3, 2007, Pages 173-179

  Jacobi, Catharina E ^a   Van Ierland, Yvette ^a   Van Asperen, Christi J ^a   Hallensleben, Eric ^b   Devilee, Peter ^a   Jan Fleuren, Gert ^a   Kenter, Gemma G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GROENE HART HOSPITAL   (Netherlands)

Author keywords

BRCA1 2 mutation; Family history; Histology; Ovarian cancer; Prediction

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; DNA DETERMINATION; ENDOMETRIUM CANCER; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC SCREENING; HETEROZYGOTE; HOSPITAL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MULTIVARIATE ANALYSIS; MUTATIONAL ANALYSIS; ONCOGENE; OVARY CANCER; PREDICTION; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; UTERUS CANCER;

EID: 34247138331     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e318032e4ab     Document Type: Article

References (40)

1. Visser O, Siesling S, van Dijck JAAM (Eds.). Incidence of cancer in the Netherlands 1999/2000. Utrecht (NL): Association of Comprehensive Cancer Centres. The Netherlands, 2003.
2. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 2003;101(5 Pt 1):885-891.
3. O'Malley CD, Cress RD, Campleman SL, Leiserowitz GS. Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study. Gynecol Oncol 2003;91:608-615.
4. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers: breast cancer linkage consortium. Am J Hum Genet 1995;56:265-271.
5. Ford D, Easton DF, Stratton M, Narod S, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-689.
6. Antoniou A, Pharoah PD, Narod S, Risch HA, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-1130.
7. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-646.
8. Boyd J. Hereditary ovarian cancer: what we know. Gynecol Oncol 2003;88(1 Pt 2):S8-S10.
9. BC Cancer Agency. FIGO classification criteria of the ovaries. http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Gynecology/ OvaryEpithelial/Staging.htm Accessed July 31, 2006.
10. Miller SA, Dykes DD, Polesky, HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
11. Davies H, Dicks E, Stephens P, Cox C, et al. High throughput DNA sequence variant detection by conformation sensitive capillary electrophoresis and automated peak comparison. Genomics 2006;87:427-432.
12. Petrij-Bosch A, Peelen, T, van Vliet M, van Eijk R, et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 1997;17:341-345.
13. Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 2003;63:1449-1453.
14. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
15. Oldenburg RA, Kroeze-Jansema K, Meijers-Heijboer H, van Asperen CJ, et al. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping. Clin Cancer Res 2006;12:1693-1700.
16. Takahashi H, Behbakht K, McGovern PE, Chiu HC, et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 1995;55:2998-3002.
17. Matsushima M, Kobayashi K, Emi M, Saito H, et al. Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation. Hum Mol Genet 1995;4:1953-1956.
18. Stratton JF, Gayther SA, Russell P, Dearden J, et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997;336:1125-1130.
19. Berchuck A, Heron KA, Carney ME, Lancaster JM, et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 1998;4:2433-2437.
20. Khoo US, Ngan HY, Cheung AN, Chan KY, et al. Mutational Analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations. Hum Mutat 2000;16:88-89.
21. Risch HA, McLaughlin JR, Cole DE, Rosen B, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-710.
22. Takahashi H, Chiu HC, Bandera CA, Behbakht K, et al. Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res 1996;56:2738-2741.
23. Foster KA, Harrington P, Kerr J, Russell P, et al. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res 1996;56:3622-3625.
24. Pal T, Permuth-Wey J, Betts JA, Krischer JP, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807-2816.
25. Chen S, Iversen ES, Friebel T, Finkelstein D, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006;24:863-871.
26. Sarantaus L, Vahteristo P, Bloom E, Tamminen A, et al. BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients. Eur J Hum Genet 2001;9:424-430.
27. Moslehi R, Chu W, Karlan B, Fishman D, et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000;66:1259-1272.
28. Anton-Culver H, Cohen PF, Gildea ME, Ziogas A. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer 2000;36:1200-1208.
29. Claes K, Poppe B, Coene I, Paepe AD, et al. BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families. Br J Cancer 2004;90:1244-1251.
30. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-1490.
31. Gayther SA, Russell P, Harrington P, Antoniou AC, et al. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet 1999;65:1021-1029.
32. Zweemer RP, Shaw PA, Verheijen RM, Ryan A, et al. Accumulation of P53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. J Clin Pathol 1999;52:372-375.
33. Werness BA, Ramus SJ, DiCioccio RA, Whittemore AS, et al. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. Int J Gynecol Pathol 2004;23:29-34.
34. Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004;10:2473-2481.
35. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996;77:2318-2324.
36. Russell PA, Pharoah PD, De Foy K, Ramus SJ, et al. Frequent loss of BRCA1 MRNA and protein expression in sporadic ovarian cancers. Int J Cancer 2000;87:317-321.
37. Rubin SC. BRCA-related ovarian carcinoma. Cancer 2003;97:2127-2129.
38. Puget N, Torchard D, Serova-Sinilnikova OM, Lynch HT, et al. A 1-Kb Alu-mediated germ-line deletion removing BRCA1 exon 17. Cancer Res 1997;57:828-831.
39. Malander S, Rambech E, Kristoffersson U, Halvarsson B, et al. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol 2006;101:238-243.
40. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-2529.